HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

Blood

Volumn 118, Issue 20, 2011, Pages 5506-5516

  Kalac, Matko ^a   Scotto, Luigi ^a   Marchi, Enrica ^a   Amengual, Jennifer ^a   Seshan, Venkatraman E ^b   Bhagat, Govind ^c   Ulahannan, Netha ^d   Leshchenko, Violetta V ^d   Temkin, Alexis M ^c   Parekh, Samir ^d   Tycko, Benjamin ^c   O'Connor, Owen A ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; AZACITIDINE; BELINOSTAT; BISULFITE; CASPASE 3; DEPSIPEPTIDE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; ROMIDEPSIN; VON HIPPEL LINDAU PROTEIN; VORINOSTAT; WT1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME ACTIVATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL LYMPHOMA; METHYLATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; XENOGRAFT;

EID: 81555196342     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-336891     Document Type: Article

References (44)

1. Pavan A, Spina M, Canzonieri V, Sansonno S, Toffoli G, De Re V. Recent prognostic factors in diffuse large B-cell lymphoma indicate NFkappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma. 2008;49(11):2048- 2058.
2. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346(4):235-241.
3. Feugier P, Van Hoof A, Sebban C, et al. Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-4126. (Pubitemid 46211317)
4. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606-613. (Pubitemid 35435172)
5. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(1):166-173. (Pubitemid 46630509)
6. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19(5):964-969. (Pubitemid 351627315)
7. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene. 2007;26(47):6697-6714. (Pubitemid 47585096)
8. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19):1350-1354.
9. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6-21. (Pubitemid 34049633)
10. Goto T, Monk M. Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev. 1998;62(2):362-378. (Pubitemid 28270279)
11. Jones PA. The DNA methylation paradox. Trends Genet. 1999;15(1):34-37. (Pubitemid 29207343)
12. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21(35):5400- 5413.
13. Bird AP, Wolffe AP. Methylation induced repression: belts, braces and chromatin. Cell. 1999; 99(5):451-454.
14. Prokhoutchouk A, Hendrich B, Jorgensen H, et al. The p120 catenin partner Kaiso is a DNA methylation- dependent transcriptional repressor. Genes Dev. 2001;15(13):1613-1618. (Pubitemid 32702582)
15. Grønbæk K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS. 2007;115(10):1039- 1059.
16. Jones PL, Veenstra GJC, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 1998;19(2): 187-191. (Pubitemid 28248804)
17. Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Azacitidine: 10 years later. Cancer Treat Rep. 1987;71(7):737-746.
18. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS: the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in177 patients. Ann Hematol. 2005; 84(suppl 1):9-17.
19. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacytidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 2005;11(10):3604-3608. (Pubitemid 40685574)
20. Yang H, Hoshino K, Sanchez-Gonzales B, Kantarjian H, Garcia-Manero G. Antileukemia activity of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res. 2005;29(7):739-748. (Pubitemid 40779480)
21. Kuendgen A, Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol. 2008;87(8):601-611.
22. Leshchenko VV, Kuo PY, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 2010;116(7):1025-1034.
23. Kumagai T, Wakimotot N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer. 2007;121(3):656-665. (Pubitemid 46986501)
24. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110(7):2303-2308.
25. Garcia-Manero G, Kantarjian HM, Sanchez- Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006; 108(10):3271-3279.
26. Voso MT, Santini V, Finelli C, et al. Valproic acid at therapeutic plasma levels may increase 5- azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res. 2009;15(15):5002- 5007.
27. Marchi E, Paoluzzi L, Scotto L, et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res. 2010; 16(14):3648-3658.
28. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood. 2008; 111(11):5350-5358.
29. Zhao L, Wientjes G, Au JLS. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004; 10(23):7994-8004. (Pubitemid 39587541)
30. Roe JS, Kim HR, Hwang IY, Cho EJ, Youn HD. Von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. Oncogene. 2011; 30(28):3127-3138.
31. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31-39. (Pubitemid 46053039)
32. Grant C, Rahman F, Piekarz R, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997-1008.
33. Quintas-Cardama A, Santos FPS, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol. 2010;7(8):433- 444.
34. Cazzola M, Malcovati L. Myelodysplastic syndromes: coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536-538. (Pubitemid 40204666)
35. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4): 562-9.
36. Kirschbaum M, Gojo I, Goldberg SL, et al. Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. ASH Annual Meeting. 2008; 112: Abstract 3651.
37. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs. 2010;70(3):273-286.
38. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
39. Shaknovich R, Geng H, Johnson NA, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010; 116(20):e81-e89.
40. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphoma. Ann Oncol. 2008;19(10):1774-1786.
41. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275. (Pubitemid 29246458)
42. Hatzimichael E, Dranitsaris G, Dasoula A, et al. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma. 2009;9(3):239-242.
43. Kanduri M, Chaill N, Göranson H, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115(2):296-305.
44. Kirschbaum M, Gojo I, Goldberg SL, et al. Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): a phase I, dose-escalation Study. Blood. 2009;114:Abstract 2089.